# Evercore

Type: Company (EVR)

Source: GetYourBrief — https://getyourbrief.com/entity/evercore
Canonical HTML page: https://getyourbrief.com/entity/evercore

## Timeline

- **2026-08-19**: Press Release Distribution — Company issues PRNewswire release summarizing the summit highlights.
- **2026-08-18**: Evercore Summit Presentation — Antengene presents R&D updates including ATG-022 clinical data, TriGager TCE platform, multiple functional modules, and ATG-207 during a fireside chat.
- **2026-08-08**: Wall Street Zen cuts STAG and ZVIA to Sell — Wall Street Zen downgraded both Stag Industrial and Zevia PBC from hold to sell in weekend research notes.
- **2026-08-05**: Q2 2026 earnings release for Lineage and Magnite — Both companies reported earnings after market close: Lineage EPS $0.76 (beat by $0.98), Magnite EPS $0.26 (beat by $0.01).
- **2026-08-05**: ZVIA reports Q2 results — Zevia PBC reported EPS of -$0.03, hitting consensus, and revenue of $45.00 million versus a $44.21 million estimate.
- **2026-07-31**: Weiss reiterates buy on STAG; Baird sets $138 target — Weiss Ratings reiterated a buy (b-) rating on Stag Industrial, while Robert W. Baird set a $138.00 target price.
- **2026-07-28**: STAG reports Q2 earnings miss — Stag Industrial reported EPS of $0.28, missing the consensus estimate of $0.65 by $0.37; revenue was approximately $224 million.
- **2026-07-21**: Lineage dividend payment date — Lineage paid quarterly dividend of $0.5325 to shareholders of record on June 30.
- **2026-07-17**: Wells Fargo raises Magnite target — Wells Fargo increased price objective from $15 to $21, maintained Equal Weight.
- **2026-07-17**: Weiss Ratings upgrades ZVIA within sell range — Weiss Ratings raised shares of Zevia PBC from a sell (e+) rating to a sell (d-) rating.
- **2026-07-16**: Barclays raises STAG target but stays Underweight — Barclays boosted its price objective on Stag Industrial from $38.00 to $41.00 and maintained an underweight rating.
- **2026-06-30**: Lineage dividend record date — Record date for Lineage's quarterly dividend of $0.5325 per share.
- **2026-06-01**: Wells Fargo cuts STAG target to $40 — Wells Fargo & Company lowered its target price on Stag Industrial from $41.00 to $40.00 and set an equal weight rating.
- **2026-05-28**: RBC reaffirms Magnite Outperform — Royal Bank of Canada reiterated an Outperform rating on Magnite shares.
- **2026-05-27**: Caisse sells 2.15M ZVIA shares — Major shareholder Caisse de dépôt et placement du Québec sold 2,150,000 shares of Zevia PBC at an average price of $1.90, totaling $4.085 million, reducing its stake by 15.87%.

## Recent coverage (20 stories, network-wide)

### Antengene Unveils 2 TCE Platforms, ATG-207 at China Summit
2026-08-23 20:02:51 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

For healthcare executives and clinical leaders, Antengene's R&D showcase highlights emerging targeted oncology and autoimmune candidates. The presentation included updated ATG-022 data and a first-in-class bifunctional fusion protein, signaling pipeline expansion that could eventually affect treatment options. Clinical teams should note the data remain limited and are not yet peer-reviewed.
Full story: https://gethealthbrief.com/story/antengene-tce-platforms-atg207-evercore-summit-health

### Antengene Debuts TriGager TCE and ATG-207 at 2nd Biotech Summit
2026-08-23 20:02:41 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

For biotech and pharma professionals, Antengene's showcase demonstrates platform depth in T-cell engager engineering, adding TriGager to its AnTenGager toolbox and introducing a first-in-class αCD3-TGF-β fusion protein. The presentation also included updated ATG-022 data, though no quantitative results were disclosed. This positions Antengene as a company to watch in the crowded CLDN18.2 and TCE arenas.
Full story: https://getbiobrief.com/story/antengene-trigager-tce-atg207-biotech-summit

### STAG Downgraded to Sell as Price Sits 38% Below $50.50 Target
2026-08-13 00:19:12 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wall Street Zen cut Stag Industrial to sell, putting a fresh bearish tilt on a REIT whose shares opened at $36.68 versus a $50.50 consensus target. The same firm also downgraded Zevia PBC as its major shareholder trimmed a 15.87% stake.
Full story: https://getfinancebrief.com/story/stag-industrial-wall-street-zen-sell-downgrade

### HSBC Grows TJX Stake by 1.1% to $480M, Analysts Set $190 Target
2026-08-12 10:50:26 · Sector: retail · Sentiment: Neutral · Impact: 5/10 · Sources: 2

HSBC's increased holding and 91% institutional ownership underline confidence in TJX's off‑price model. With analysts projecting a $190 price target, the retailer's brick-and-mortar treasure-hunt experience continues to attract both consumer and institutional capital, defying e-commerce pressures.
Full story: https://getretailbrief.com/story/hsbc-tjx-stake-increase-480m-retail

### ARE Revenue Hits $662.78M But Lab Real Estate Faces Tech Adoption Pressure
2026-08-12 00:15:00 · Sector: proptech · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Alexandria Real Estate Equities reported Q2 revenue of $662.78M, beating estimates, but a sharp EPS miss and cautious analyst outlook raise questions about how PropTech investments in smart labs and energy management will weather a softening biotech leasing market. The REIT’s guidance of $6.35-$6.45 EPS anchors expectations for rent growth and operational efficiency gains.
Full story: https://getproptechbrief.com/story/are-lab-real-estate-proptech-q2-2026

### ARE Stock Rises 3.2% Despite $0.52 EPS Miss: FY26 Guidance Saves the Quarter
2026-08-12 00:14:53 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Alexandria Real Estate Equities shares climbed 3.2% to $53.08 after Q2 revenue of $662.78M beat estimates, even as EPS missed by $0.52. The FY 2026 EPS guidance of $6.35-$6.45 provides a stalwart midpoint against a choppy analyst landscape, while a 5.4% dividend yield offers a cushion for income investors.
Full story: https://getfinancebrief.com/story/are-q2-2026-earnings-stock-rise-guidance

### ARE Q2 Revenue $662.78M: What Biotech Tenants Should Expect from FY’26 Guidance
2026-08-12 00:14:45 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

As the dominant landlord to pharma and startup labs, Alexandria’s FY 2026 EPS guidance of $6.35-$6.45—and its Q2 revenue beat of $662.78M—carry major implications for R&D real estate costs. While lease rates keep rising, a -36% net margin hints at stress in the sector that could eventually impact tenant concessions and space availability.
Full story: https://getbiobrief.com/story/alexandria-biotech-tenant-implications-fy26

### Lineage EPS Beats by $0.98, but Cold Storage Revenue Growth Stalls to 0.8%
2026-08-09 13:39:35 · Sector: supply · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Lineage, a leading cold storage REIT, reported a massive EPS beat but negligible revenue growth, highlighting softness in food logistics demand. The negative dividend payout ratio raises sustainability questions for income-focused investors.
Full story: https://getsupplybrief.com/story/lineage-earnings-beat-supply-chain

### Magnite Revenue Hits $192.8M (+11.3%), Beats by $0.01 EPS on CTV Strength
2026-08-09 13:39:27 · Sector: marketing · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Magnite's Q2 adtech earnings surpassed estimates, driven by 11.3% revenue growth, robust net margins of 21.96%, and a strong analyst consensus. The stock dip belies underlying platform health and CTV momentum.
Full story: https://getmarketingbrief.com/story/magnite-earnings-beat-adtech

### Earnings Face-Off: Lineage $0.98 Beat vs Magnite $0.01 Beat—Which Stock Wins?
2026-08-09 13:39:19 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Two disparate earnings beats: Lineage posted a massive $0.98 EPS surprise but carries negative margins, while Magnite delivered a smaller beat with solid profitability. The comparison reveals risks in chasing headline beats and highlights valuation disconnects.
Full story: https://getfinancebrief.com/story/lineage-magnite-earnings-comparison

### Apollo's £5.7B easyJet Buyout: UK PE Exodus Heats Up
2026-08-08 14:55:45 · Sector: finance · Sentiment: Positive · Impact: 6/10 · Sources: 2

Apollo Global Management’s £5.7 billion all-cash offer for easyJet, backed by the founder, highlights private equity’s hunger for discounted London-listed assets. With Castlelake out, the path is clearer, but EU ownership rules pose a significant regulatory wrinkle.
Full story: https://getfinancebrief.com/story/apollo-easyjet-takeover-finance

### Apollo's $7.7B easyJet Buyout: PE's Next Bet in Undervalued UK
2026-08-08 14:53:38 · Sector: finance · Sentiment: Neutral · Impact: 7/10 · Sources: 2

Apollo Global’s £5.7 billion all-cash bid for easyJet underscores private equity’s appetite for discounted UK assets. The deal triggers EU ownership scrutiny, while Castlelake’s withdrawal signals competitive dynamics in large-cap takeovers.
Full story: https://getfinancebrief.com/story/apollo-7-7-billion-easyjet-takeover-finance

### CBRE Ups FY2026 EPS View to $7.80-$7.90 as Real Estate Tech Demand Booms
2026-08-05 14:17:03 · Sector: proptech · Sentiment: Neutral · Impact: 5/10 · Sources: 2

CBRE Group's above-consensus EPS guidance underscores the commercial real estate sector's momentum, driven by technology-driven services. For PropTech startups and investors, it signals growing client spending on smart buildings, data analytics, and digital brokerage platforms.
Full story: https://getproptechbrief.com/story/cbre-fy2026-guidance-proptech

### Teva's $1.91-$2.11 EPS Guidance Misses Consensus, Testing Pharma Resilience
2026-08-05 14:16:51 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Teva Pharmaceutical's FY2026 EPS guidance fell short of the $2.17 consensus, while revenue projections of $16.5-$16.9B matched expectations. For healthcare leaders, the miss underscores ongoing generic drug pricing pressures and the importance of a diversified pipeline.
Full story: https://gethealthbrief.com/story/teva-fy2026-guidance-health

### Teva's $1.91-$2.11 EPS Outlook Misses as Biotech Investors Weigh Risk-Reward
2026-08-05 14:16:40 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Teva's fiscal 2026 EPS guidance, well below the Street's $2.17, raises red flags for biotech and pharma investors. However, a $42 average price target and stable revenue suggest a value play if the biosimilar pipeline delivers.
Full story: https://getbiobrief.com/story/teva-fy2026-guidance-biotech

### CPKC's $2.93B quarterly revenue signals 12.6% growth for North American freight
2026-08-03 17:03:01 · Sector: supply · Sentiment: Neutral · Impact: 6/10 · Sources: 2

CPKC's Q2 earnings beat, with revenue up 12.6% to $2.93 billion, highlights robust cross-border rail demand. For supply chain professionals, the performance reflects strong trade flows and network integration benefits post-merger.
Full story: https://getsupplybrief.com/story/cpkc-q2-2026-supply-chain-impact

### CPKC beats Q2 estimates with $0.92 EPS; analysts see 16% upside to $105
2026-08-03 17:02:51 · Sector: finance · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Canadian Pacific Kansas City posted a $0.03 EPS beat and 12.6% revenue growth, maintaining strong margins. With a consensus Buy rating and price targets as high as $105, the stock offers a defensive growth story for investors.
Full story: https://getfinancebrief.com/story/cpkc-q2-2026-earnings-beat-finance

### Sun Communities' FY26 EPS Guidance Tops $6.93 Consensus With $7.10 High-End
2026-07-28 01:45:35 · Sector: proptech · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Sun Communities’ FY 2026 EPS guidance of $6.94–$7.10, surpassing consensus, signals resilience in manufactured housing REITs. The update, alongside a massive Q2 loss, highlights the need for operational technology to improve asset performance and expense control.
Full story: https://getproptechbrief.com/story/sun-communities-fy26-guidance-proptech-implications

### Sun Communities Guides FY26 EPS to $7.10 High-End, 15% Below Avg Analyst Target
2026-07-28 01:45:22 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Sun Communities’ FY 2026 EPS guidance of $6.94–$7.10 beat the $6.93 consensus, but shares fell 0.4% on heavy volume as revenue guidance was absent. Analyst targets average $140.05, suggesting 15% upside from $121.30 despite recent price target cuts.
Full story: https://getfinancebrief.com/story/sun-communities-fy26-guidance-finance-market-impact

### Morgan Stanley Cuts BlackRock Target to $1,383, Still Sees 34% Upside
2026-07-15 21:49:56 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Morgan Stanley lowered its BlackRock (BLK) price target to $1,383 while maintaining Overweight, implying a 34% gain. The consensus remains Moderate Buy with an average target of $1,270.72. Diverging analyst revisions signal both caution and opportunity for the asset management giant.
Full story: https://getfinancebrief.com/story/blackrock-price-target-cut-morgan-stanley-1383-upside

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.